IL139419D0 - Monoclonal antibodies, cross-reactive antibodies and method for producing the same - Google Patents

Monoclonal antibodies, cross-reactive antibodies and method for producing the same

Info

Publication number
IL139419D0
IL139419D0 IL13941999A IL13941999A IL139419D0 IL 139419 D0 IL139419 D0 IL 139419D0 IL 13941999 A IL13941999 A IL 13941999A IL 13941999 A IL13941999 A IL 13941999A IL 139419 D0 IL139419 D0 IL 139419D0
Authority
IL
Israel
Prior art keywords
antibodies
producing
cross
same
method
Prior art date
Application number
IL13941999A
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US9663798A priority Critical
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to PCT/US1999/013197 priority patent/WO1999064461A2/en
Publication of IL139419D0 publication Critical patent/IL139419D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
IL13941999A 1998-06-12 1999-06-10 Monoclonal antibodies, cross-reactive antibodies and method for producing the same IL139419D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US9663798A true 1998-06-12 1998-06-12
PCT/US1999/013197 WO1999064461A2 (en) 1998-06-12 1999-06-10 Monoclonal antibodies, cross-reactive antibodies and method for producing the same

Publications (1)

Publication Number Publication Date
IL139419D0 true IL139419D0 (en) 2001-11-25

Family

ID=22258333

Family Applications (3)

Application Number Title Priority Date Filing Date
IL13941999A IL139419D0 (en) 1998-06-12 1999-06-10 Monoclonal antibodies, cross-reactive antibodies and method for producing the same
IL139419A IL139419A (en) 1998-06-12 2000-11-01 Antibodies which cross-react with apo-2l receptor and compositions comprising them
IL200056A IL200056A (en) 1998-06-12 2009-07-23 Composition comprising an isolated agonistic antibody which specifically cross reacts with different apo - 2l receptors for use in inducing apoptosis in mammalian cancer cells

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL139419A IL139419A (en) 1998-06-12 2000-11-01 Antibodies which cross-react with apo-2l receptor and compositions comprising them
IL200056A IL200056A (en) 1998-06-12 2009-07-23 Composition comprising an isolated agonistic antibody which specifically cross reacts with different apo - 2l receptors for use in inducing apoptosis in mammalian cancer cells

Country Status (12)

Country Link
US (1) US20060177456A1 (en)
EP (2) EP1086138B1 (en)
JP (2) JP2002517223A (en)
AT (1) AT443723T (en)
AU (1) AU4561199A (en)
CA (1) CA2328498A1 (en)
DE (1) DE69941453D1 (en)
ES (2) ES2395693T3 (en)
HK (1) HK1132750A1 (en)
IL (3) IL139419D0 (en)
PT (1) PT1086138E (en)
WO (1) WO1999064461A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528239B1 (en) 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
PT1181319E (en) * 1999-05-28 2009-07-14 Genentech Inc Chimeric dr4 antibodies and uses thereof
HU0300369A2 (en) 2000-04-11 2003-06-28 Genentech, Inc. Multivalent antibodies and their applications
AU2001297702A1 (en) * 2000-11-08 2002-10-15 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
DE10157336B4 (en) * 2000-11-24 2007-07-19 Bioserv Analytik Und Medizinprodukte Gmbh A process for preparing a test system and diagnostic methods for the detection of pancreatic dysfunction
US7115717B2 (en) 2001-05-18 2006-10-03 Kirin Beer Kabushiki Kaisha Anti-TRAIL-R antibodies
WO2003066661A2 (en) 2001-07-03 2003-08-14 Genentech, Inc. Human dr4 antibodies and uses thereof
JP2007530588A (en) 2004-03-23 2007-11-01 バイオジェン・アイデック・エムエイ・インコーポレイテッド Receptor coupling agent and its therapeutic applications
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
PE11012007A1 (en) 2005-08-31 2007-12-21 Amgen Inc Polypeptides and antibodies
EP2727942A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Bispecific antibodies against human EGFR, HER2, and HER3
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
US20150259430A1 (en) 2012-11-05 2015-09-17 Mab Discovery Gmbh Method for the production of multispecific antibodies
EP2727943A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Trispecific antibodies against human EGFR, HER2 and HER3

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) * 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) * 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) * 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) * 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) * 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) * 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
JPS6023084B2 (en) * 1979-07-11 1985-06-05 Ajinomoto Kk
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4419446A (en) * 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4870009A (en) * 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4601978A (en) * 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPH0340B2 (en) * 1983-11-09 1991-01-07 Aichi Prefecture
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
EP0206448B1 (en) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5153118A (en) * 1985-12-17 1992-10-06 Eastern Virginia Medical Authority Monoclonal antibodies having binding specificity to human prostate tumor-associated antigens and methods for employing the same
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IL85035D0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5010182A (en) * 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
DE3850542T2 (en) 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antibody heteroconjugates to Töting of HIV-infected cells.
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
CA1306430C (en) * 1987-10-16 1992-08-18 Kenneth Francis Bradstock Monoclonal antibody
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5453359A (en) 1988-06-13 1995-09-26 American Biogenetic Sciences, Inc. Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE69029036T2 (en) 1989-06-29 1997-05-22 Medarex Inc Bispecific reagents for AIDS Therapy
AU648261B2 (en) * 1989-08-18 1994-04-21 Novartis Vaccines And Diagnostics, Inc. Recombinant retroviruses delivering vector constructs to target cells
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ES2139598T3 (en) 1990-07-10 2000-02-16 Medical Res Council Procedures for producing members of specific binding partners.
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3540315B2 (en) 1991-09-23 2004-07-07 ケンブリッジ アンティボディー テクノロジー リミティド Production of chimeric antibodies - a combination approach
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0546073T3 (en) 1990-08-29 1998-02-02 Genpharm Int Making and using transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5206161A (en) * 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
US5216126A (en) * 1991-06-19 1993-06-01 Genentech, Inc. Receptor polypeptides and their production and uses
AU2147192A (en) 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
DE69233745D1 (en) 1991-12-02 2008-10-23 Cambridge Antibody Tech Production of autoantibodies on phage surfaces starting from antibody segment libraries
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1993022343A1 (en) * 1992-05-01 1993-11-11 The Rockfeller University Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
RU2139731C1 (en) 1992-11-13 1999-10-20 Айдек Фармасьютикалс Корпорейшн (US Methods of treatment, antibodies, hybridoma
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
WO1994029348A2 (en) 1993-06-03 1994-12-22 Therapeutic Antibodies Inc. Production of antibody fragments
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
US5877016A (en) * 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
NZ311982A (en) * 1995-06-29 1999-08-30 Immunex Corp Tnf related apoptosis inducing ligand (trail), a method for producing them and associated antibodies
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6046048A (en) * 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US6635743B1 (en) * 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US6462176B1 (en) * 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US6455040B1 (en) * 1997-01-14 2002-09-24 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
US6072047A (en) * 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US7528239B1 (en) * 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US6313269B1 (en) * 1997-03-14 2001-11-06 Smithkline Beecham Corporation Tumor necrosis factor related receptor, TR6
US20050233958A1 (en) * 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
US6872568B1 (en) * 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
DK0970213T3 (en) * 1997-03-17 2007-05-21 Human Genome Sciences Inc Dödsdomæneholdig receptor
WO1998046643A1 (en) * 1997-04-16 1998-10-22 Millennium Biotherapeutics, Inc. TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEINS TANGO-63d AND TANGO-63e
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
ES2293682T5 (en) * 1997-05-15 2011-11-17 Genentech, Inc. Anti-apo2.
WO1999009165A1 (en) * 1997-08-15 1999-02-25 Idun Pharmaceuticals, Inc. Trail receptors, nucleic acids encoding the same, and methods of use thereof
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
US7279160B2 (en) * 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US20020048566A1 (en) * 2000-09-14 2002-04-25 El-Deiry Wafik S. Modulation of cellular apoptosis and methods for treating cancer
US6689744B2 (en) * 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
US20020160446A1 (en) * 2000-11-14 2002-10-31 Holtzman Douglas A. Novel genes encoding proteins having prognostic diagnostic preventive therapeutic and other uses
CN1610696A (en) * 2001-12-20 2005-04-27 人体基因组科学有限公司 Antibodies that immunospecifically bind to TRAIL receptors

Also Published As

Publication number Publication date
DE69941453D1 (en) 2009-11-05
JP2002517223A (en) 2002-06-18
IL200056A (en) 2010-12-30
ES2331901T3 (en) 2010-01-19
US20060177456A1 (en) 2006-08-10
AT443723T (en) 2009-10-15
PT1086138E (en) 2010-01-04
EP2058334A2 (en) 2009-05-13
AU4561199A (en) 1999-12-30
EP1086138A2 (en) 2001-03-28
IL139419A (en) 2010-12-30
ES2395693T3 (en) 2013-02-14
EP2058334B1 (en) 2012-10-31
WO1999064461A2 (en) 1999-12-16
WO1999064461A3 (en) 2000-04-20
EP1086138B1 (en) 2009-09-23
HK1132750A1 (en) 2013-06-14
CA2328498A1 (en) 1999-12-16
EP2058334A3 (en) 2009-05-20
WO1999064461A9 (en) 2001-06-28
JP2009112318A (en) 2009-05-28

Similar Documents

Publication Publication Date Title
DK1037926T3 (en) TREATMENT WITH ANTI-ErbB2 ANTIBODIES
AU696286B2 (en) Recombinant humanized anti-lewis Y antibodies
AP1590A (en) Human monoclonal antibodies to CTLA-4
AU735355C (en) Novel protein and method for producing the protein
GB2334957B (en) Monovalent antibody fragments
AU695419B2 (en) Method for detecting antibodies
EP0667541A3 (en) Optical functional materials and process for producing the same.
AU5181698A (en) Optoelectronic material, device using the same, and method for manufacturing optoelectronic material
IL138497A (en) Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
HK1025631A1 (en) Antibody against psma or antigen binding portion thereof, as well as their use.
IL193752D0 (en) Apo-2 ligand antibodies and hybridoma cell lines which produce them
AU731817C (en) Humanized anti-CD11a antibodies
IL143674D0 (en) Metalloproteinase inhibitors, and the methods for making these
AU2001231172A1 (en) Methods and compositions for generating human monoclonal antibodies
EP0854730A4 (en) High affinity human monoclonal antibodies specific for rsv f-protein
AU2250992A (en) Method for making humanized antibodies
ZA9901307B (en) Antibodies against human CD40.
GR3017734T3 (en) Humanised antibodies.
AU5447499A (en) Exposure apparatus and exposure method, and device and method for producing the same
PT973550E (en) Anti-integrine antibodies anti-integrina avb3
PL206576B1 (en) Novel streptococcus antigens
PL330111A1 (en) Concentyratyed antibody preparation
LT2330129T (en) Anti-tnf antibodies, compositions, methods and uses
IL158643A (en) Anti-hmg monoclonal antibodies and compositions containing the same
GEPI20105118B (en) Anti-vegf antibodies